Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jiangyi He"'
Autor:
Wulin Lei, Lan Yu, Shangyu Bai, Yanfeng Chen, Feng Zhao, Chao Zheng, Xu Huang, Jiangyi He, Hualong Zhou
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract In order to safeguard the surface structures from mining damage while optimizing the liberation of coal resources under the dense surface buildings of the Cedi River coal mine. Considering that the analysis of the structure and type of surfa
Externí odkaz:
https://doaj.org/article/72feabc2f4334b0690685388975ab356
Autor:
Yan Gu, Yanrong Chen, Lai Wei, Shuang Wu, Kaicheng Shen, Chengxiang Liu, Yan Dong, Yang Zhao, Yue Zhang, Chi Zhang, Wenling Zheng, Jiangyi He, Yunlong Wang, Yifei Li, Xiaoxin Zhao, Hongwei Wang, Jun Tan, Liting Wang, Qi Zhou, Ganfeng Xie, Houjie Liang, Juanjuan Ou
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
This study reveals an unrecognized role of ABHD5 in regulating colon cancer stemness via controlling YAP methylation and nuclear localization, further explaining the molecular mechanism through which ABHD5 functions as a tumour suppressor gene in col
Externí odkaz:
https://doaj.org/article/33c740cbfc424f82b51a157bae061d41
Autor:
Yan Gu, Yanrong Chen, Lai Wei, Shuang Wu, Kaicheng Shen, Chengxiang Liu, Yan Dong, Yang Zhao, Yue Zhang, Chi Zhang, Wenling Zheng, Jiangyi He, Yunlong Wang, Yifei Li, Xiaoxin Zhao, Hongwei Wang, Jun Tan, Liting Wang, Qi Zhou, Ganfeng Xie, Houjie Liang, Juanjuan Ou
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/08d95234971d4fe19cc8db0a06c8e12e
Autor:
Yang Zhao, Jun Tan, Jianjun Hu, Hongwei Wang, Yue Zhang, Chi Zhang, Yunlong Wang, Yan Dong, Yanli Guo, Juanjuan Ou, Houjie Liang, Junyi Wang, Jiangyi He, Kejing Fang, Yanrong Chen, Ruiyang Zi, Chengxiang Liu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background The poor immunogenicity of solid tumors limits the efficacy ofanti-programmed cell death protein 1 (anti-PD1)-based immune checkpoint blockade (ICB); thus, less than 30% of patients with cancer exhibit a response. Currently, there is still
Externí odkaz:
https://doaj.org/article/b388a33f2f4147a68ab717fa2f0d97e4
Publikováno v:
International Journal of Minerals, Metallurgy and Materials. 30:1398-1406
Autor:
Xin Li, Xiaomeng Fan, Wenjie Zhu, Xiaoke Lu, Jianyong Tu, Jiangyi He, Jimei Xue, Fang Ye, Yongsheng Liu, Laifei Cheng
Publikováno v:
Journal of the European Ceramic Society. 43:1459-1468
Autor:
Chi Zhang, Shuang Wu, Jiangyi He, Yue Zhang, Yifei Li, Yang Zhao, Ganfeng Xie, Chengxiang Liu, Yunlong Wang, Yanrong Chen, Qi Zhou, Hongwei Wang, Houjie Liang, Xiaoxin Zhao, Yan Dong, Kaicheng Shen, Jun Tan, Yan Gu, Liting Wang, Wenling Zheng, Juanjuan Ou, Lai Wei
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Nature Communications
Nature Communications
Cancer stemness represents a major source of development and progression of colorectal cancer (CRC). c-Met critically contributes to CRC stemness, but how c-Met is activated in CRC remains elusive. We previously identified the lipolytic factor ABHD5
Autor:
Jiangyi He, Maojun Zhou
Publikováno v:
Journal of environmental and public health. 2022
The COVID-19 pandemic is a worldwide catastrophe. In the absence of an effective drug, one effective measure to pull the pandemic to the end is herd immunity by taking vaccines, while the hesitation and anti-attitude from social media affect the vacc
Autor:
Xiao, Luo, Jiangyi, He, Xiaochong, Liu, Youliang, Xu, Jian, Li, Xiaojun, Guo, Qianru, Wang, Longbiao, Li
Publikováno v:
Materials (Basel, Switzerland). 15(6)
In this paper, the 12k T-700
Autor:
Jianjun Hu, Jiangyi He, Yunlong Wang, Yang Zhao, Kejing Fang, Yan Dong, Yanrong Chen, Yue Zhang, Chi Zhang, Hongwei Wang, Jun Tan, Junyi Wang, Ruiyang Zi, Chengxiang Liu, Houjie Liang, Yanli Guo, Juanjuan Ou
Publikováno v:
Journal for immunotherapy of cancer. 10(3)
BackgroundThe poor immunogenicity of solid tumors limits the efficacy ofanti-programmed cell death protein 1 (anti-PD1)-based immune checkpoint blockade (ICB); thus, less than 30% of patients with cancer exhibit a response. Currently, there is still